IMGO Stock Overview
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$17.84|
|52 Week High||US$35.68|
|52 Week Low||US$14.61|
|1 Month Change||-22.94%|
|3 Month Change||-31.93%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||9.52%|
Recent News & Updates
We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|IMGO||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how IMGO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IMGO performed against the US Market.
|IMGO Average Weekly Movement||14.8%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: IMGO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: IMGO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Imago BioSciences Fundamentals Summary
|IMGO fundamental statistics|
Is IMGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMGO income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.99|
|Net Profit Margin||0.00%|
How did IMGO perform over the long term?See historical performance and comparison
Is Imago BioSciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMGO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMGO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMGO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: IMGO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMGO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMGO is overvalued based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2x).
How is Imago BioSciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMGO is forecast to have no revenue next year.
High Growth Revenue: IMGO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMGO's Return on Equity is forecast to be high in 3 years time
How has Imago BioSciences performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: IMGO is currently unprofitable.
Growing Profit Margin: IMGO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IMGO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IMGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: IMGO has a negative Return on Equity (-14.51%), as it is currently unprofitable.
How is Imago BioSciences's financial position?
Financial Position Analysis
Short Term Liabilities: IMGO's short term assets ($234.6M) exceed its short term liabilities ($8.9M).
Long Term Liabilities: IMGO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IMGO is debt free.
Reducing Debt: IMGO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMGO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IMGO has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 54.2% each year.
What is Imago BioSciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMGO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hugh Rienhoff (68 yo)
Dr. Hugh Young Rienhoff, Jr., M.D., serves as Chairman of the Board at Parvus Therapeutics Inc. since July 16, 2019. Dr. Rienhoff serves as a Managing Director of Life Science Venture Partners. Dr. Rienhof...
CEO Compensation Analysis
Compensation vs Market: Hugh's total compensation ($USD732.63K) is below average for companies of similar size in the US market ($USD1.70M).
Compensation vs Earnings: Insufficient data to compare Hugh's compensation with company performance.
Experienced Management: IMGO's management team is seasoned and experienced (9.8 years average tenure).
Experienced Board: IMGO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: IMGO only recently listed within the past 12 months.
Imago BioSciences, Inc.'s employee growth, exchange listings and data sources
- Name: Imago BioSciences, Inc.
- Ticker: IMGO
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$598.152m
- Shares outstanding: 33.53m
- Website: https://www.imagobio.com
Number of Employees
- Imago BioSciences, Inc.
- 329 Oyster Point Boulevard
- 3rd Floor
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 00:12|
|End of Day Share Price||2022/01/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.